Predict your next investment

Memorial Sloan Kettering Cancer Center company logo
Corporation
HEALTHCARE | Medical Facilities & Services / Hospitals
mskcc.org

See what CB Insights has to offer

Investments

6

Portfolio Exits

1

Partners & Customers

10

About Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center is committed to patient care, research, and educational programs. Its education programs train future physicians and scientists.

Memorial Sloan Kettering Cancer Center Headquarter Location

1275 York Avenue

New York, New York, 10065,

United States

212-639-2000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Memorial Sloan Kettering Cancer Center

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Memorial Sloan Kettering Cancer Center in 1 Expert Collection, including HLTH.

H

HLTH

92 items

HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare

Memorial Sloan Kettering Cancer Center Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Memorial Sloan Kettering Cancer Center Rank

Research containing Memorial Sloan Kettering Cancer Center

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Memorial Sloan Kettering Cancer Center in 1 CB Insights research brief, most recently on May 9, 2019.

Latest Memorial Sloan Kettering Cancer Center News

Prevencio and Memorial Sloan Kettering Cancer Center Data Demonstrates Significant Correlation of AI-driven HART CVE Blood Test Scores with Development of Adverse Heart Events Following Cancer Radiation Treatment

Oct 27, 2021

Data Highlighted at American Society for Radiation Oncology (ASTRO) Scientific Sessions October 27, 2021 09:00 AM Eastern Daylight Time KIRKLAND, Wash.--( BUSINESS WIRE )-- Prevencio, Inc. today announces the presentation of data demonstrating that its Artificial Intelligence (AI) driven HART CVE blood test scores strongly correlate with subsequent adverse cardiac events in lung cancer patients undergoing radiation treatment. Researchers and clinicians from Memorial Sloan Kettering Cancer Center collaborated to test their lung cancer population. “With cancer patients living longer, understanding the adverse cardiac effects due to cancer treatments, such as radiation therapy, is of utmost importance,” said Annemarie Shepherd, M.D., Assistant Member in Radiation Oncology Cancer Center. “We analyzed serial patient blood samples before, during and after radiation treatment and interestingly found a significant correlation between an increase in the HART CVE scores during radiation and the development of cardiac events in follow up after radiation.” Charles B. Simone, M.D., Chief Medical Officer of the New York Proton Center and Member in Radiation Oncology at Memorial Sloan Kettering Cancer Center, added, “It is critical that we identify more sensitive means of predicting which patients will have adverse cardiac events from radiation therapy, and we are pleased to collaborate with Prevencio to use their novel machine learning-based HART CVE test to do so.” In the general cardiac population, HART CVE had previously been reported to be more accurate (86% AUC accuracy) at predicting risk of heart attack, stroke or cardiac death as compared to single protein blood tests, such as high sensitivity troponin (~65% accuracy), and clinical risk scores (~57% AUC accuracy). “It is gratifying to work with Dr. Shepherd and Dr. Simone and their team at Memorial Sloan Kettering Cancer Center to demonstrate HART CVE’s usefulness in their lung cancer patients,” said Rhonda Rhyne, President and Chief Executive Officer of Prevencio. “We believe our tests will also prove helpful for breast and esophageal cancer patients undergoing radiation therapy.” In the U.S., lung cancer is the second most common cancer in both men and women, with approximately 235,760 new cases annually. Currently, there are more than 550,000 lung cancer patients in the U.S. Prevencio recently launched for patient use its two lead tests, HART CVE (for one-year risk of heart attack, stroke, or cardiac death) and HART CADhs (for obstructive heart disease diagnosis). For additional information, visit Prevencio, Inc. About Prevencio HART Tests: Powered by AI, Prevencio is revolutionizing blood tests for cardiovascular disease and custom diagnostics. Employing this novel approach, the Company has developed seven blood tests that significantly improve diagnosis and risk assessment for a variety of heart and blood vessel-related complications. Our three lead tests include: HART CVE™ – 1-year risk of heart attack, stroke, or cardiac death HART CADhs™ – obstructive coronary artery disease diagnosis HART KD™ – Kawasaki disease diagnosis HART test results have been peer-reviewed published 25 times, including at leading cardiovascular meetings—(European Society of Cardiology Congress – 2016, 2018, 2021; American College of Cardiology Scientific Sessions – 2017, 2018, 2019 (2), 2020, 2021; American Heart Association Scientific Sessions – 2017, 2018, 2019; American Diabetes Association Scientific Sessions – 2018, 2019; Pediatric Academic Societies International Sessions – 2021; International Spinal Cord Society Scientific Sessions –2021; ASTRO Scientific Sessions – 2021) and in top-tier journals—(Journal of American College of Cardiology – Mar 2017; American Journal of Cardiology – July 2017; Clinical Cardiology – June 2018; Open Heart – November 2018, May 2019, Jan 2019; Biomarkers in Medicine – June 2020; Journal of American Heart Association – Aug 2020). About Prevencio, Inc.: Prevencio's value proposition is "Preventing the Preventable” — That is, preventing unnecessary procedures, related side effects, and expense, as well as improving patient outcomes and clinical trials through more accurate blood tests for Cardiovascular Disease conditions. Prevencio utilizes Machine Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers + Proprietary Algorithms to deliver cardiovascular diagnostic & prognostic tests that are significantly more accurate than standard-of-care stress tests. The Company is headquartered in Kirkland, Washington. For additional information, visit Prevencio, Inc. Forward-Looking (Safe Harbor) Statement: Except for historical and factual information contained herein, this press release contains forward-looking statements, such as market need, acceptance, and size, the accuracy of which is necessarily subject to various uncertainties of development-stage companies. The Company does not undertake to update disclosures contained in this press release. Contacts

Memorial Sloan Kettering Cancer Center Investments

6 Investments

Memorial Sloan Kettering Cancer Center has made 6 investments. Their latest investment was in Blue Note Therapeutics as part of their Series A - II on September 9, 2021.

CBI Logo

Memorial Sloan Kettering Cancer Center Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/9/2021

Series A - II

Blue Note Therapeutics

$5.2M

Yes

1

6/1/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

8/9/2019

Series D

Subscribe to see more

$99M

Subscribe to see more

10

2/21/2018

Series C

Subscribe to see more

$99M

Subscribe to see more

10

2/13/2018

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/9/2021

6/1/2021

8/9/2019

2/21/2018

2/13/2018

Round

Series A - II

Series B

Series D

Series C

Series C

Company

Blue Note Therapeutics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$5.2M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

10

10

Memorial Sloan Kettering Cancer Center Portfolio Exits

1 Portfolio Exit

Memorial Sloan Kettering Cancer Center has 1 portfolio exit. Their latest portfolio exit was ORIC Pharmaceuticals on April 24, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/24/2020

IPO

$991

4

Date

4/24/2020

Exit

IPO

Companies

Valuation

$991

Acquirer

Sources

4

Memorial Sloan Kettering Cancer Center Acquisitions

2 Acquisitions

Memorial Sloan Kettering Cancer Center acquired 2 companies. Their latest acquisition was Ralph Lauren Center for Cancer Care and Prevention on August 08, 2018.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

8/8/2018

$991

Acquired

1

2/4/2018

Series C - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/8/2018

2/4/2018

Investment Stage

Series C - II

Companies

Subscribe to see more

Valuation

$991

Total Funding

$99M

Note

Acquired

Subscribe to see more

Sources

1

10

Memorial Sloan Kettering Cancer Center Partners & Customers

10 Partners and customers

Memorial Sloan Kettering Cancer Center has 10 strategic partners and customers. Memorial Sloan Kettering Cancer Center recently partnered with Blue Note Pharmaceuticals on September 9, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

9/15/2021

Partner

Blue Note Pharmaceuticals

United States

1

9/14/2021

Partner

Blue Note Therapeutics

United States

09:00 ET Blue Note Therapeutics Announces New Collaboration for its Prescription Digital Therapeutic Candidate

`` We are excited for this opportunity to further our partnership with Memorial Sloan Kettering Cancer Center , '' said Geoffrey Eich , CEO of Blue Note Therapeutics .

2

2/23/2021

Partner

Carrum Health

United States

7/9/2020

Licensee

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

6/22/2020

Licensee

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

9/15/2021

9/14/2021

2/23/2021

7/9/2020

6/22/2020

Type

Partner

Partner

Partner

Licensee

Licensee

Business Partner

Blue Note Pharmaceuticals

Blue Note Therapeutics

Carrum Health

Country

United States

United States

United States

Subscribe to see more

Subscribe to see more

News Snippet

09:00 ET Blue Note Therapeutics Announces New Collaboration for its Prescription Digital Therapeutic Candidate

`` We are excited for this opportunity to further our partnership with Memorial Sloan Kettering Cancer Center , '' said Geoffrey Eich , CEO of Blue Note Therapeutics .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

2

10

10

Memorial Sloan Kettering Cancer Center Team

24 Team Members

Memorial Sloan Kettering Cancer Center has 24 team members, including current Chief Financial Officer, Michael Harrington.

Name

Work History

Title

Status

Michael Harrington

Chief Financial Officer

Current

Claus Torp Jensen

Chief Technology Officer, Chief Information Officer

Current

Daniel Stein MD PhD

Chief Information Officer

Current

Brian Loomis

Chief Marketing Officer

Current

Jonathan Reichel

Peace Corps, and Howard Hughes Medical Institute

Chief Marketing Officer

Current

Name

Michael Harrington

Claus Torp Jensen

Daniel Stein MD PhD

Brian Loomis

Jonathan Reichel

Work History

Peace Corps, and Howard Hughes Medical Institute

Title

Chief Financial Officer

Chief Technology Officer, Chief Information Officer

Chief Information Officer

Chief Marketing Officer

Chief Marketing Officer

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.